GSK - GlaxoSmithKline plc
| Previous Close | 40.46 |
| Open | 40.69 |
| Bid | 40.96 x 1300 |
| Ask | 41.00 x 800 |
| Day's Range | 40.64 - 41.00 |
| 52 Week Range | 34.52 - 42.36 |
| Volume | 2,603,995 |
| Avg. Volume | 2,462,823 |
| Market Cap | 104.957B |
| Beta | 0.66 |
| PE Ratio (TTM) | 73.70 |
| EPS (TTM) | 0.55 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 2.17 (5.29%) |
| Ex-Dividend Date | 2018-05-10 |
| 1y Target Est | 42.19 |
- Zacks•2 hours ago
Glaxo, J&J's Dual Drug HIV Regimen Succeeds in Phase III Study
Glaxo (GSK) and Johnson and Johnson report positive top line results from a late-stage study of their injectable two-drug regimen for the treatment of HIV.
- Market Realist•17 hours ago
Gauging Analysts’ Expectations for Novavax and Peers in August
Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.
- Motley Fool•23 hours ago
Should Gilead Be Worried About This New Monthly HIV Medication?
The devil is in the undisclosed details.
Reuters•2 days agoLong-acting injection a shot in the arm for GSK's HIV business
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.
- Reuters•2 days ago
Commodities slide pulls FTSE to three-and-a-half month closing low
By Kit Rees and Helen Reid LONDON (Reuters) - Britain's top share index sank on Wednesday as emerging markets stress and a sharp selloff in commodities drove down stocks across Europe, with investors running ...
Reuters•2 days agoLong-acting injection a shot in the arm for GSK's HIV business
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.
- CNBC•2 days ago
Stocks making the biggest moves premarket: M, STZ, EGN, GSK, WMT & more
Macy's M – The retailer earned an adjusted 70 cents per share for the second quarter, topping estimates, with revenue also beating forecasts. Comparable sales posted an unexpected rise of 0.5 percent, compared to forecasts of a 0.
- Market Realist•2 days ago
Analysts’ Recommendations for GlaxoSmithKline Stock
This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.
- The Wall Street Journal•2 days ago
[$$] European Corporate Roundup for Wednesday
European Corporate Roundup for Wednesday Admiral Group 1H Interim Profit Rose on Motor-Unit Growth Admiral Group PLC said Wednesday that its first-half profit rose on growth in its core U.K. motor-insurance business, despite poor weather hurting its household unit.
- Financial Times•2 days ago
[$$] GSK sees positive signs from trials of reduced HIV treatment
GlaxoSmithKline’s HIV division has welcomed the results of a trial that could see the drug regime of patients cut from a daily dose of three drugs to a monthly injection of two. ViiV Healthcare hopes that developing the two-drug products will boost GSK’s share of the $20bn-a-year market for HIV treatment, addressing toxicity concerns among people living with HIV by reducing the number of medicines they need to take. In the case of the injectable version, ViiV wants to be able to free HIV patients from having to take daily treatment.
- Reuters•2 days ago
Long-acting injection boosts hopes for GSK's HIV business
A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's ...
Market Realist•3 days agoA Look at Novo Nordisk’s Human Insulin and Obesity Business
In the first half of 2018, Novo Nordisk’s (NVO) human insulin generated revenues of 4.7 billion Danish kroner, a ~1% YoY (year-over-year) growth in local currencies.
- Market Realist•3 days ago
Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.
- Market Realist•3 days ago
What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.
- Market Realist•3 days ago
GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products. In the second quarter, Pharmaceuticals revenue grew 1% YoY (year-over-year) to ~4.23 billion British pounds at constant exchange rates.
- Motley Fool•3 days ago
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
Which stock wins in a matchup between these two big pharma companies?
- The Wall Street Journal•4 days ago
[$$] Orchard Therapeutics Raises $150 Million After GlaxoSmithKline Deal
Orchard Therapeutics has raised $150 million after bulking up its portfolio of gene therapies through an agreement with GlaxoSmithKline.
- Market Realist•4 days ago
How GlaxoSmithKline’s Segments Have Performed
As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...
Market Realist•4 days agoCan Victoza Continue to Boost Novo Nordisk’s Revenue Growth?
Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.
- Market Realist•4 days ago
Analyzing GlaxoSmithKline’s Revenue Trends
In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.
- Market Realist•4 days ago
How GlaxoSmithKline’s Valuation Compares with Peers’
Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017.
- Reuters•4 days ago
Orchard raises $150 million to expand after GSK gene therapy deal
Anglo-American biotech company Orchard Therapeutics has raised a further $150 million (117.7 million pounds) to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million (109.8 million pounds). The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline (GSK.L) rare disease medicines, including the gene therapy Strimvelis for ADA severe combined immune deficiency (ADA-SCID), or "bubble baby" disease. Gene therapy is a hot area for drug research - highlighted by Novartis's (NOVN.S) $8.7 billion (6.8 billion pounds) acquisition of AveXis in April - but products sold to Orchard are viewed as too niche for GSK as it refocuses its drug research under CEO Emma Walmsley.
- Reuters•4 days ago
Orchard raises $150 mln to expand after GSK gene therapy deal
Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million. The new financing comes four months after its acquisition of a portfolio of GlaxoSmithKline rare disease medicines, including the gene therapy Strimvelis for ADA severe combined immune deficiency (ADA-SCID), or "bubble baby" disease. Gene therapy is a hot area for drug research - highlighted by Novartis's $8.7 billion acquisition of AveXis in April - but products sold to Orchard are viewed as too niche for GSK as it refocuses its drug research under CEO Emma Walmsley.
- American City Business Journals•7 days ago
In $270M Peninsula vaccine company buyout, small players look to be big shots
A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.
- CNBC Videos•7 days ago
The traders weigh in on Square, GlaxoSmithKline and Dropb...
The "Halftime Report" traders take viewer questions on ORBCOMM, Square, GlaxoSmithKline, Royal Dutch Shell and Dropbox.
